Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials

Journal of Biomedical Science

Review

Men-Luh Yen¹  Huey-Kang Sytwu²  Ko-Jiunn Liu³  B. Linju Yen⁴  Chiao-Hsuan Ting⁴  Kenneth K. Wu⁵  Li-Tzu Wang⁶ 

[1] Department of Ob/Gyn, National Taiwan University Hospital & College of Medicine, National Taiwan University, Taipei, Taiwan;Graduate Institute of Life Sciences, National Defense Medical Center (NDMC), Taipei, Taiwan;Graduate Institute of Microbiology and Immunology, NDMC, Taipei, Taiwan;National Institute of Cancer Research, NHRI, Tainan, Taiwan;Regenerative Medicine Research Group, Institute of Cellular & System Medicine, National Health Research Institutes (NHRI), 35 Keyan Road, 35053, Zhunan, Taiwan;Regenerative Medicine Research Group, Institute of Cellular & System Medicine, National Health Research Institutes (NHRI), 35 Keyan Road, 35053, Zhunan, Taiwan;Graduate Institute of Basic Medical Sciences, China Medical College, Taichung, Taiwan;Regenerative Medicine Research Group, Institute of Cellular & System Medicine, National Health Research Institutes (NHRI), 35 Keyan Road, 35053, Zhunan, Taiwan;Graduate Institute of Life Sciences, National Defense Medical Center (NDMC), Taipei, Taiwan;

关键词: Mesenchymal stem cells;    Human;    Immunomodulation;    Inflammation;    Clinical trials;    Autoimmune disease;    Organ transplantation and rejection;    Stem cell therapy;   

DOI  :  10.1186/s12929-016-0289-5

 received in 2016-06-23, accepted in 2016-10-12,  发布年份 2016

来源: Springer

【 摘 要 】

Human mesenchymal stem cells (MSCs) are multilineage somatic progenitor/stem cells that have been shown to possess immunomodulatory properties in recent years. Initially met with much skepticism, MSC immunomodulation has now been well reproduced across tissue sources and species to be clinically relevant. This has opened up the use of these versatile cells for application as 3rd party/allogeneic use in cell replacement/tissue regeneration, as well as for immune- and inflammation-mediated disease entities. Most surprisingly, use of MSCs for in immune-/inflammation-mediated diseases appears to yield more efficacy than for regenerative medicine, since engraftment of the exogenous cell does not appear necessary. In this review, we focus on this non-traditional clinical use of a tissue-specific stem cell, and highlight important findings and trends in this exciting area of stem cell therapy.

【 授权许可】

CC BY   
© The Author(s). 2016